Outlook Therapeutics (OTLK) Cash from Operations (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Cash from Operations of 7828055.0 for Q1 2026, up 52.8% year-over-year from 5123179.17 in Q1 2025, and up 47.6% quarter-over-quarter from 14939111.0 in Q4 2025.
Outlook Therapeutics (OTLK) Cash from Operations (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Cash from Operations for 12 consecutive years, with 7828055.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 52.8% year-over-year to 7828055.0; the TTM figure through Mar 2026 stood at 47045522.0 (up 26.54% YoY), while the FY2025 annual figure was 51829437.0, up 24.66% from the prior year.
- Cash from Operations advanced to 7828055.0 in Q1 2026 per OTLK's latest filing, from 14939111.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 7828055.0 in Q1 2026 and bottomed at 21099242.0 in Q2 2022.
- Historically, Cash from Operations has averaged 13649891.76 across 5 years, with a median of 13032169.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations slumped 137.44% — and 2026, when it jumped 52.8%.
- Outlook Therapeutics' Cash from Operations stood at 8901246.0 in 2022, then sank by 46.41% to 13032169.0 in 2023, then grew by 15.84% to 10967335.0 in 2024, then tumbled by 36.21% to 14939111.0 in 2025, then surged by 47.6% to 7828055.0 in 2026.
- Business Quant data shows OTLK's Cash from Operations at 7828055.0 in Q1 2026, 14939111.0 in Q4 2025, and 12377197.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | -21.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.83 Mn |
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Dec 31, 2025 | -14.94 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Sep 30, 2025 | -12.38 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -11.90 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Jun 30, 2024 | -19.51 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Mar 31, 2024 | -19.27 Mn |
| Dec 31, 2023 | -13.03 Mn |
| Dec 31, 2023 | -13.03 Mn |